Today: 21 May 2026
Browse Category

NYSE:MHK 6 December 2025 - 9 January 2026

Mohawk Industries stock jumps again as housing-rate bets return after Trump mortgage-bond plan

Mohawk Industries stock jumps again as housing-rate bets return after Trump mortgage-bond plan

Mohawk Industries shares climbed about 3% to $117.70 in late morning Friday trading after a 6.9% surge Thursday, topping the 200-day moving average. Wolfe Research downgraded the stock to “Peer Perform,” citing weak prospects for a renovation rebound in early 2026. Traders are watching interest rates and the $114 price level. U.S. job growth slowed in December, with unemployment at 4.4%.
9 January 2026
···
Mohawk Industries (MHK) Stock Outlook – December 6, 2025: Earnings Beat, Fitch Rating and Analyst Targets Explained

Mohawk Industries (MHK) Stock Outlook – December 6, 2025: Earnings Beat, Fitch Rating and Analyst Targets Explained

Mohawk Industries traded at $110.69 per share on December 6, 2025, with a market cap near $6.9 billion. The stock is up about 7% year-to-date, lagging the S&P 500, and sits 23% below its 52-week high. Fitch affirmed its BBB+ rating with a Stable outlook after an earnings beat. Technical signals remain negative, and analysts cite ongoing demand concerns.
6 December 2025
·

Stock Market Today

  • Teradyne, Kulicke and Soffa, Impinj, Microchip, IPG Photonics Stocks Slide on U.S.-China Semiconductor Summit Outcome
    May 21, 2026, 2:58 AM EDT. Shares of Teradyne, Kulicke and Soffa, Impinj, Microchip Technology, and IPG Photonics dropped sharply following the U.S.-China summit, which ended without key breakthroughs on semiconductor exports. Expectations for U.S. approval of Nvidia's H200 chip shipments to China were unmet, disappointing investors. U.S. Trade Representative Jamieson Greer indicated semiconductors were not a negotiation focus, dampening near-term optimism. Despite the sell-off, IPG Photonics' stock, known for volatility, remains down significantly from its 52-week high but has gained 34.3% year-to-date. Market reactions highlight cautious sentiment amid geopolitical tensions, with analysts skeptical about swift comprehensive deals due to national security concerns.

Latest articles

SPAC ETF Up as SpaceX Heads for SPCX Ticker

SPAC ETF Up as SpaceX Heads for SPCX Ticker

21 May 2026
The SPAC and New Issue ETF, now trading as SPCK, closed up 0.64% at $22.09 on Wednesday after SpaceX filed for a $75 billion IPO under the fund’s old ticker. The fund reported $7.14 million in net assets and 41 holdings as of May 19. New listings included a $75 million IPO from Research Alliance III and filings from FutureCorp Space Acquisition 1 and JAB Acquisition I. The SEC proposed easing share issuance rules for public companies.
EnerSys Stock Flips After Earnings as Guidance Tops Trader Hopes

EnerSys Stock Flips After Earnings as Guidance Tops Trader Hopes

21 May 2026
EnerSys shares rose in after-hours trading after the company posted fourth-quarter adjusted earnings of $3.19 per share on $988 million in revenue, both above analyst estimates. The stock closed regular hours down 1.3% at $214.56, then quoted up 5.8% to $227. First-quarter profit guidance also topped forecasts. Management cited strong data center and defense demand, but noted continued weakness in motive-power and transportation.
Silexion Soars After Cancer Study, Liquidity and Nasdaq Issues Linger for SLXN

Silexion Soars After Cancer Study, Liquidity and Nasdaq Issues Linger for SLXN

21 May 2026
Silexion Therapeutics shares surged 97% to $0.5298 on Wednesday with over 325 million shares traded, then fell 9.5% after hours. The move followed news that Israel approved a Phase 2/3 trial of its lead pancreatic cancer drug, SIL204. Silexion reported a Q1 net loss of $2.7 million and $2.4 million in cash. The company plans a 1-for-10 reverse share split by early June.
Go toTop